SAN DIEGO, June 11, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today the appointment of Nick Glover, Ph.D., to its Board of Directors. Dr. Glover was most recently President and Chief Executive Officer of YM BioSciences, an oncology drug development company acquired by Gilead Sciences for $510 million in February 2013. The appointment of Dr. Glover increases MEI Pharma's board to seven members, including six independent directors.
"Dr. Glover is a natural fit to round out our Board of Directors, adding a wealth of relevant strategic and operational knowledge," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of MEI Pharma. "In addition to firsthand experience leading an emerging hematology drug development company, Nick has an extensive background in business development and strong relationships within the life science investment community. We look forward to the benefit of his experience as we execute multiple Phase II clinical trials of Pracinostat in the months ahead and formulate strategies for maximizing its value."
Dr. Glover served as President and Chief Executive Officer of YM BioSciences from November 2010 until the completion of its acquisition by Gilead. YM's lead drug candidate, CYT387, was an orally administered JAK inhibitor being developed for the treatment of myelofibrosis. Previously, Dr. Glover was President and Chief Executive Officer of Viventia Biotech, a biopharmaceutical company involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer. Prior to joining Viventia, he was an investment manager at MDS Capital, a life sciences venture capital firm. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., and a Ph.D. in Chemistry from Simon Fraser University, Canada."I am pleased to be joining the board of MEI Pharma at such an exciting time," said Dr. Glover. "The Company has a very promising lead drug candidate, Pracinostat, which has the potential to be both clinically and commercially differentiated. In addition, MEI Pharma is led by an excellent team, and I look forward to working with management and the board to assist in the Company's advancement."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts